Literature DB >> 27822748

Suppression of Ehrlich carcinoma growth by cobra venom factor.

T I Terpinskaya1, V S Ulashchik1, A V Osipov2, V I Tsetlin3, Yu N Utkin3.   

Abstract

Cobra venom factor (CVF) depletes the complement system of the blood by forming stable convertase C3/C5 of the alternative pathway. We found that CVF from the Thailand cobra venom slows down the growth of subcutaneous Ehrlich carcinoma (EC) in mice at a dose of 1.7 nmol/g. Previously, we described a similar effect for the nerve growth factor (NGF) from the venom of this cobra. However, these factors did not exhibit either synergy or additive effect. On the contrary, they neutralized the antitumor effect of each other when they were administered simultaneously. Therefore, on the one hand, the NGF antitumor effect against EC manifests itself under the conditions of inflammation, and normal functioning of the complement system is necessary for this effect to occur. On the other hand, suppression of the humoral immune system leads to a slowdown of the EC growth, but administration of NGF prevents this.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27822748     DOI: 10.1134/S0012496616050021

Source DB:  PubMed          Journal:  Dokl Biol Sci        ISSN: 0012-4966


  12 in total

1.  Two forms of nerve growth factor from cobra venom prevent the death of PC12 cells in serum-free medium.

Authors:  V V Kukhtina; V I Tsetlin; Y N Utkin; L S Inozemtseva; I A Grivennikov
Journal:  J Nat Toxins       Date:  2001-02

2.  Naja melanoleuca cobra venom contains two forms of complement-depleting factor (CVF).

Authors:  Alexey V Osipov; Dmitry Yu Mordvintsev; Vladislav G Starkov; Lyudviga V Galebskaya; Elena V Ryumina; Peter P Bel'tyukov; Leonid V Kozlov; Sergey V Romanov; Yvon Doljansky; Victor I Tsetlin; Yuri N Utkin
Journal:  Toxicon       Date:  2005-09-15       Impact factor: 3.033

3.  Enhancement of the complement activating capacity of 17-1A mAb to overcome the effect of membrane-bound complement regulatory proteins on colorectal carcinoma.

Authors:  Kyra A Gelderman; Peter J K Kuppen; Wouter Bruin; Gert Jan Fleuren; Arko Gorter
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

4.  Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.

Authors:  Leticia Corrales; Daniel Ajona; Stavros Rafail; Juan J Lasarte; Jose I Riezu-Boj; John D Lambris; Ana Rouzaut; Maria J Pajares; Luis M Montuenga; Ruben Pio
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

5.  Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.

Authors:  Chunmei Piao; Lun Cai; Shulan Qiu; Lixin Jia; Wenchao Song; Jie Du
Journal:  J Biol Chem       Date:  2015-03-04       Impact factor: 5.157

6.  Transient complement inhibition promotes a tumor-specific immune response through the implication of natural killer cells.

Authors:  Valérie Janelle; Marie-Pierre Langlois; Esther Tarrab; Pascal Lapierre; Laurent Poliquin; Alain Lamarre
Journal:  Cancer Immunol Res       Date:  2013-12-05       Impact factor: 11.151

7.  Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.

Authors:  Siao-Yi Wang; Suresh Veeramani; Emilian Racila; Jeffrey Cagley; David C Fritzinger; Carl-Wilhelm Vogel; William St John; George J Weiner
Journal:  Blood       Date:  2009-10-05       Impact factor: 22.113

Review 8.  Inflammation and cancer: advances and new agents.

Authors:  Shanthini M Crusz; Frances R Balkwill
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

Review 9.  Tumor macroenvironment and metabolism.

Authors:  Wael Al-Zoughbi; Wael Al-Zhoughbi; Jianfeng Huang; Ganapathy S Paramasivan; Holger Till; Martin Pichler; Barbara Guertl-Lackner; Gerald Hoefler
Journal:  Semin Oncol       Date:  2014-03-01       Impact factor: 4.929

10.  Nerve growth factor from cobra venom inhibits the growth of Ehrlich tumor in mice.

Authors:  Alexey V Osipov; Tatiana I Terpinskaya; Elena V Kryukova; Vladimir S Ulaschik; Lubov V Paulovets; Elena A Petrova; Ekaterina V Blagun; Vladislav G Starkov; Yuri N Utkin
Journal:  Toxins (Basel)       Date:  2014-02-26       Impact factor: 4.546

View more
  2 in total

1.  Cobra Venom Factor and Ketoprofen Abolish the Antitumor Effect of Nerve Growth Factor from Cobra Venom.

Authors:  Alexey V Osipov; Tatiana I Terpinskaya; Tatiana E Kuznetsova; Elena L Ryzhkovskaya; Vladimir S Lukashevich; Julia A Rudnichenko; Vladimir S Ulashchyk; Vladislav G Starkov; Yuri N Utkin
Journal:  Toxins (Basel)       Date:  2017-09-06       Impact factor: 4.546

2.  First Look at the Venom of Naja ashei.

Authors:  Konrad Kamil Hus; Justyna Buczkowicz; Vladimír Petrilla; Monika Petrillová; Andrzej Łyskowski; Jaroslav Legáth; Aleksandra Bocian
Journal:  Molecules       Date:  2018-03-08       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.